Project Grant R01HL171480
Award Date 6/1/24
Completion Date 4/30/28
Dollars Obligated $3.7M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Louisiana State University Health Sciences Center-Shreveport a Project Grant of $659,441 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic science research investigating nutrient sensing mechanisms in macrophage-mediated clearance of apoptotic cells. The research, which commenced August 15, 2025, and extends through May 31, 2029, seeks to elucidate the molecular pathways...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports basic and translational research investigating the role of leucine metabolism in atherosclerosis development. The University of Pittsburgh received $788,863 in obligated funding for the project period from May 1, 2026, through February 28, 2030. The research will deliver scientific outputs focused on manipulating leucine uptake,...
- Federal Project Grant Award Summary Louisiana State University Health Sciences Center-Shreveport received a $737,242 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026, with completion targeted for January 31, 2030. The research project investigates macrophage one-carbon metabolism's role in atherosclerotic plaque stability, with the goal of identifying novel therapeutic targets to...
- This Project Grant award of $405,350.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to characterize lipid droplets in macrophage subsets and determine if manipulating lipid droplet content can shift macrophage function, with the goal of uncovering new therapeutic targets for systemic lupus erythematosus (SLE). The award recipient is The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New York University's Long Island School of Medicine a Project Grant totaling $2,728,306 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using microRNA-30C analog C2. The research initiative, which commenced on September 24, 2025, and extends through August 31, 2027, focuses on developing and validating a novel synthetic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1,151,500 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) to investigate novel concepts in macrophage biology and their roles in atherosclerotic cardiovascular disease and cardiometabolic disease. The award, obligated on March 9, 2026, with a completion date of February 28, 2033, supports a comprehensive research program examining the...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Connecticut Health Center a $227,878 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective June 20, 2025, with completion targeted for January 31, 2028. This research initiative investigates the role of TRPM7 (Transient Receptor Potential Protein, Melastatin Family Member 7) in macrophage-mediated atherosclerosis development. The project will generate...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Kentucky Research Foundation a $249,000 Project Grant effective May 1, 2026, through March 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports basic research investigating transgelin's (TAGLN) role in low-density lipoprotein (LDL) metabolism and atherosclerosis. The research will characterize TAGLN's interactions with LDL endocytic machinery, determine its impact on LDL...
- This Project Grant award of $528,179, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research conducted by the University of Miami to investigate reprogramming of monocytes to improve neovascularization in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effects of monocyte reprogramming, and 2) investigate how reduced expression of the...
- Federal Grant Award Summary The University of Arizona received a $1.47M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of May 31, 2029. The award funds basic research investigating the role of hepatocyte transmembrane protein 141 (TMEM141) in lipoprotein metabolism and atherosclerosis. The research team will utilize genetically modified mouse models and...